SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor

Publication | Closed Access

DOI

354

Citations

References

2017

Year

Yumei Ye, Mandeep Bajaj, Hsiu-Chiung Yang, J. R. Perez‐Polo, Yochai Birnbaum

Cardiovascular Drugs and Therapy

Metabolic SyndromeDiabetes ManagementCardiovascular DiseaseSglt-2 InhibitionMedicineDiabetesImmunologyType 2Dpp4 InhibitorDiabetes MellitusPharmacology